Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - colecalciferol, quantity: 0.14 mg; alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sucrose; butylated hydroxytoluene; croscarmellose sodium; microcrystalline cellulose; gelatin; medium chain triglycerides; colloidal anhydrous silica - alendronate plus d3 70 mg/140 microgram apotex are indicated for the treatment of: osteoporosis in select patients where vitamin d supplementation is recommended, prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: gelatin; povidone; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; medium chain triglycerides; butylated hydroxytoluene; magnesium stearate; sucrose - alendronate plus d3 70 mg/70 microgram apotex are indicated for the treatment of: osteoporosis in select patients where vitamin d supplementation is recommended, prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sumitomo chemical australia pty. limited - fenitrothion - emulsifiable concentrate - fenitrothion organophosphorus active 1000.0 g/l - insecticide - apple | broiler poultry house,litter,wall & roof | cabbage | cereal crop | cherry | feed bin | feed shed | grain storage area an - australian plague locust | black beetle | corbie | flour beetles | grain weevil | indian meal moth | lesser grain borer | lesser mealworm | migratory locust | oxycanus grass grub | pasture cockchafer | sawtoothed grain beetle | sitona weevil | spur-throated locust | stored grain insect pests | tropical warehouse moth | underground grass grub | wingless grasshopper | winter corbie | black beetle | darkling beetle | grain borer | litter beetle | nomadacris guttulosa | sitophilus granarius | sitophilus oryzae | sitophilus zeamais | tribolium castaneum | tribolium confusum | tribolium spp.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 32841 - mobile-bearing total knee prosthesis - a sterile implantable artificial substitute for a knee joint designed to maintain the connection between the two articualting components.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stryker australia pty ltd - 32841 - mobile-bearing total knee prosthesis - a sterile implantable artificial substitute for a knee joint designed to provide a secondary bearing surface and a soft hyperextension stop within the tibial component.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arjo australia pty ltd - 58419 - mobile bariatric examination/treatment chair - medicare bariatric 3 section couch

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

surgeons choice australia pty ltd - 42280 - mobile specimen x-ray system, digital - a mobile cabinet x ray system used to provide digital images of specimens, not for use on humans.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - melaleuca oil, quantity: 1 ml/ml (equivalent: cineole, qty 0.06 ml/ml) - liquid, multipurpose - excipient ingredients: - antiseptic oil. a naturally sourced antiseptic. apply to minor cuts, burns, abrasions, pimples, boils, bites and stings.,maximum strength. cuts & abrasions, pimples, blocked nose / sinus. nail infections, insect bites, athletes foot.